0000950142-24-001490.txt : 20240530 0000950142-24-001490.hdr.sgml : 20240530 20240530180952 ACCESSION NUMBER: 0000950142-24-001490 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240529 FILED AS OF DATE: 20240530 DATE AS OF CHANGE: 20240530 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eckelman Brendan P. CENTRAL INDEX KEY: 0001766433 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42031 FILM NUMBER: 241006989 MAIL ADDRESS: STREET 1: C/O INHIBRX, INC. STREET 2: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibrx Biosciences, Inc. CENTRAL INDEX KEY: 0002007919 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990613523 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 140 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 140 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Ibex SpinCo, Inc. DATE OF NAME CHANGE: 20240111 4 1 es240484860_4-eckelman.xml OWNERSHIP DOCUMENT X0508 4 2024-05-29 0 0002007919 Inhibrx Biosciences, Inc. INXB 0001766433 Eckelman Brendan P. C/O INHIBRX BIOSCIENCES, INC. 11025 NORTH TORREY PINES ROAD, SUITE 140 LA JOLLA CA 92037 0 1 0 0 Chief Scientific Officer 0 Common Stock 2024-05-29 4 A 0 433888 A 433888 I By the Eckelman Living Trust Dated February 5, 2014 Common Stock 2024-05-29 4 A 0 40000 A 40000 I By trust Common Stock 2024-05-29 4 A 0 40000 A 40000 I By trust Stock Option (right to buy) 15.86 2024-05-30 4 A 0 175000 0.00 A 2034-05-30 Common Stock 175000 175000 D The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014. These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust. These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust. This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. Twenty-five percent (25%) of the total shares subject to this stock option will become exercisable on May 30, 2025, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter. /s/ Kelly D. Deck, Chief Financial Officer of Inhibrx Biosciences, Inc., as attorney-in-fact 2024-05-30